UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events

Annals of the rheumatic diseases, 2009-07, Vol.68 (7), p.1136-1145

2009

Volltextzugriff (PDF)

Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study

Annals of the rheumatic diseases, 2009-06, Vol.68 (6), p.789-796

2009

Volltextzugriff (PDF)

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

Annals of the rheumatic diseases, 2008-11, Vol.67 (11), p.1516-1523

2008

Volltextzugriff (PDF)

Determining the Minimally Important Difference in the Clinical Disease Activity Index for Improvement and Worsening in Early Rheumatoid Arthritis Patients

Arthritis care & research (2010), 2015-10, Vol.67 (10), p.1345-1353

2015

Volltextzugriff (PDF)

POS0445 PHYSICIAN AND PATIENT REPORTED EFFECTIVENESS OUTCOMES ARE SIMILAR IN TOFACITINIB AND TNF INHIBITORS IN RHEUMATOID ARTHRITIS PATIENTS: DATA FROM A RHEUMATOID ARTHRITIS REGISTRY IN CANADA

Annals of the rheumatic diseases, 2021-06, Vol.80 (Suppl 1), p.452-452

2021

Volltextzugriff (PDF)

Biosimilars in immune‐mediated inflammatory diseases: initial lessons from the first approved biosimilar anti‐tumour necrosis factor monoclonal antibody

Journal of internal medicine, 2016-01, Vol.279 (1), p.41-59

2016

Volltextzugriff (PDF)

Updated consensus statement on biological agents, specifically tumour necrosis factor α (TNFα) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005

Annals of the rheumatic diseases, 2005-11, Vol.64 (suppl 4), p.iv2-iv14

2005

Volltextzugriff (PDF)

Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study

Annals of the rheumatic diseases, 2006-06, Vol.65 (6), p.753-759

2006

Volltextzugriff (PDF)

Consensus statement on the use of rituximab in patients with rheumatoid arthritis

Annals of the Rheumatic Diseases, 2007-02, Vol.66 (2), p.143-150

2007

Volltextzugriff (PDF)

POS0448 DISCONTINUATION RATE OF TOFACITINIB AS MONOTHERAPY IS SIMILAR COMPARED TO COMBINATION THERAPY WITH METHOTREXATE IN RHEUMATOID ARTHRITIS PATIENTS: POOLED DATA FROM TWO RHEUMATOID ARTHRITIS REGISTRIES IN CANADA

Annals of the rheumatic diseases, 2021-06, Vol.80 (Suppl 1), p.454-454

2021

Volltextzugriff (PDF)

Health Assessment Questionnaire at One Year Predicts All‐Cause Mortality in Patients With Early Rheumatoid Arthritis

Arthritis & rheumatology (Hoboken, N.J.), 2021-02, Vol.73 (2), p.197-202

2021

Volltextzugriff (PDF)

The utility of tumour necrosis factor blockade in orphan diseases

Annals of the rheumatic diseases, 2004-11, Vol.63 (suppl 2), p.ii79-ii83

Keystone, E C

2004

Volltextzugriff (PDF)

Treating rheumatoid arthritis to target: recommendations of an international task force

Annals of the Rheumatic Diseases, 2010-04, Vol.69 (4), p.631-637

2010

Volltextzugriff (PDF)

Efficacy of initial methotrexate monotherapy versus combination therapy with a biological agent in early rheumatoid arthritis: a meta-analysis of clinical and radiographic remission

Annals of the rheumatic diseases, 2010-07, Vol.69 (7), p.1298-1304

2010

Volltextzugriff (PDF)

Impact of immunogenicity on efficacy and tolerability of tumour necrosis factor inhibitors: pooled analysis of biosimilar studies in rheumatoid arthritis

Scandinavian journal of rheumatology, 2020-09, Vol.49 (5), p.361-370

2020

Volltextzugriff (PDF)

Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade

Annals of the rheumatic diseases, 2009-06, Vol.68 (6), p.823-827

2009

Volltextzugriff (PDF)

Determining best practices in early rheumatoid arthritis by comparing differences in treatment at sites in the Canadian Early Arthritis Cohort

Journal of rheumatology, 2013-11, Vol.40 (11), p.1823-1830

2013

Volltextzugriff (PDF)

Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial

Annals of internal medicine, 1999-03, Vol.130 (6), p.478

1999

Volltextzugriff (PDF)

POS0651 CLINICAL AND FUNCTIONAL RESPONSE TO TOFACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS: PROBABILITY PLOT ANALYSIS OF RESULTS FROM A 48-WEEK PHASE 3b/4 METHOTREXATE WITHDRAWAL STUDY

Annals of the rheumatic diseases, 2021-06, Vol.80 (Suppl 1), p.564-565

2021

Volltextzugriff (PDF)

POS1459-HPR IDENTIFYING MEANINGFUL CHANGE IN THE RA FLARE QUESTIONNAIRE SCORES IN RHEUMATOID ARTHRITIS

Annals of the rheumatic diseases, 2021-06, Vol.80 (Suppl 1), p.1014-1015

2021

Volltextzugriff (PDF)

POS0531 FACTORS ASSOCIATED WITH BASELINE HYPERTENSION IN EARLY RHEUMATOID ARTHRITIS: DATA FROM A REAL-WORLD LARGE INCIDENT COHORT

Annals of the rheumatic diseases, 2021-06, Vol.80 (Suppl 1), p.499-500

2021

Volltextzugriff (PDF)

Advances in targeted therapy: safety of biological agents

Annals of the rheumatic diseases, 2003-11, Vol.62 (suppl 2), p.ii34-ii36

Keystone, E C

2003

Volltextzugriff (PDF)

Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies

Annals of the rheumatic diseases, 2009-02, Vol.68 (2), p.216-221

2009

Volltextzugriff (PDF)

SAT0127 REAL-WORLD PREDICTORS OF STARTING DIFFERENT ADVANCED DMARD TREATMENTS IN RHEUMATOID ARTHRITIS: A PROSPECTIVE INVESTIGATION FROM THE CANADIAN EARLY ARTHRITIS COHORT (CATCH) GROUP

Annals of the rheumatic diseases, 2020-06, Vol.79 (Suppl 1), p.999-1000

2020

Volltextzugriff (PDF)

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011

Annals of the rheumatic diseases, 2012-04, Vol.71 (Suppl 2), p.i2-i45

2012

Volltextzugriff (PDF)

1 – 25 von 664

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(573)
Mit Volltextzugriff
(479)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(349)
Science & Technology
(344)
Life Sciences & Biomedicine
(340)
Rheumatology
(232)
Female
(210)
Male
(203)
Middle Aged
(181)
Biological And Medical Sciences
(174)
Adult
(170)
Medical Sciences
(167)
Rheumatoid Arthritis
(161)
Arthritis, Rheumatoid - Drug Therapy
(141)
Antirheumatic Agents - Therapeutic Use
(109)
Aged
(98)
Diseases Of The Osteoarticular System
(97)
Inflammatory Joint Diseases
(90)
Treatment Outcome
(86)
Patients
(71)
Severity Of Illness Index
(64)
Medicin Och Hälsovetenskap
(61)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events

Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

Determining the Minimally Important Difference in the Clinical Disease Activity Index for Improvement and Worsening in Early Rheumatoid Arthritis Patients

POS0445 PHYSICIAN AND PATIENT REPORTED EFFECTIVENESS OUTCOMES ARE SIMILAR IN TOFACITINIB AND TNF INHIBITORS IN RHEUMATOID ARTHRITIS PATIENTS: DATA FROM A RHEUMATOID ARTHRITIS REGISTRY IN CANADA

Biosimilars in immune‐mediated inflammatory diseases: initial lessons from the first approved biosimilar anti‐tumour necrosis factor monoclonal antibody

Updated consensus statement on biological agents, specifically tumour necrosis factor α (TNFα) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005

Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study

Consensus statement on the use of rituximab in patients with rheumatoid arthritis

POS0448 DISCONTINUATION RATE OF TOFACITINIB AS MONOTHERAPY IS SIMILAR COMPARED TO COMBINATION THERAPY WITH METHOTREXATE IN RHEUMATOID ARTHRITIS PATIENTS: POOLED DATA FROM TWO RHEUMATOID ARTHRITIS REGISTRIES IN CANADA

Health Assessment Questionnaire at One Year Predicts All‐Cause Mortality in Patients With Early Rheumatoid Arthritis

The utility of tumour necrosis factor blockade in orphan diseases

Treating rheumatoid arthritis to target: recommendations of an international task force

Efficacy of initial methotrexate monotherapy versus combination therapy with a biological agent in early rheumatoid arthritis: a meta-analysis of clinical and radiographic remission

Impact of immunogenicity on efficacy and tolerability of tumour necrosis factor inhibitors: pooled analysis of biosimilar studies in rheumatoid arthritis

Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade

Determining best practices in early rheumatoid arthritis by comparing differences in treatment at sites in the Canadian Early Arthritis Cohort

Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial

POS0651 CLINICAL AND FUNCTIONAL RESPONSE TO TOFACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS: PROBABILITY PLOT ANALYSIS OF RESULTS FROM A 48-WEEK PHASE 3b/4 METHOTREXATE WITHDRAWAL STUDY

POS1459-HPR IDENTIFYING MEANINGFUL CHANGE IN THE RA FLARE QUESTIONNAIRE SCORES IN RHEUMATOID ARTHRITIS

POS0531 FACTORS ASSOCIATED WITH BASELINE HYPERTENSION IN EARLY RHEUMATOID ARTHRITIS: DATA FROM A REAL-WORLD LARGE INCIDENT COHORT

Advances in targeted therapy: safety of biological agents

Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies

SAT0127 REAL-WORLD PREDICTORS OF STARTING DIFFERENT ADVANCED DMARD TREATMENTS IN RHEUMATOID ARTHRITIS: A PROSPECTIVE INVESTIGATION FROM THE CANADIAN EARLY ARTHRITIS COHORT (CATCH) GROUP

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011

Suchergebnisse filtern